St. Jude Patent Proposes Senolytics for Sickle Cell Disease
A pending St. Jude patent proposes treating sickle cell disease complications with senolytic drugs that selectively eliminate senescent cells; the accessible excerpt does not specify agents, doses, or experimental results.
Patent application WO2025064402A1, filed by St. Jude Children's Research Hospital and published March 27, 2025, proposes treating sickle cell disease complications with senolytics. Senolytics selectively eliminate senescent (aging) cells. These cells accumulate with age and resist apoptosis (programmed cell death). Senolytics alter the signaling pathways of these cells: they restore the cells' ability to undergo apoptosis or trigger it directly. The filing names dasatinib, quercetin, fisetin, and navitoclax as examples.
The listed inventors are Shannon McKinney-Freeman and Aditya Barve. The patent's keywords include hematopoietic stem cells (HSCs) and mice, but the available excerpt does not specify which agent, dose, or schedule is proposed. The full patent text is substantially longer than the accessible excerpt, so we cannot determine whether it contains experimental data. The application is pending.
WO2025064402A1 · Senolytics on Eternal Search
Sources
[1] Method for treating sickle cell disease by targeting senescent cells
The edge is substantive: the patent text directly names senolytics, defines the class, and lists specific agents (dasatinib, quercetin, fisetin, navitoclax), making this a genuine conceptual extension of senolytic applications beyond age-related disease rather than a loose keyword match.